

 BeiGene →  BeOnc

# Clinical Trials Appendix

Q4 2024 Results Update

February 27, 2025




# Disclosures

Certain statements contained in this presentation and in any accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include statements regarding the projected dates for upcoming regulatory approvals; and BeiGene's research, discovery, and pre-clinical and early-stage clinical programs and plans. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and medicines; BeiGene's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene's ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled "Risk Factors" in BeiGene's most recent periodic report filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the SEC. All information in this presentation is as of the date of this presentation, and BeiGene undertakes no duty to update such information unless required by law.




# Our Pipeline Snapshot

Across three therapy areas:




Clinical studies run by BeiGene



Clinical and commercial stage assets



Patients enrolled in clinical trials globally\*



Approvals for BRUKINSA® (zanubrutinib) globally

\*Includes investigator initiated trials (IITs)

# BeiGene: Upcoming Regulatory Action Catalysts 1H 2025 – 1H 2026

## Potential Approvals

### 1H, 2025

#### Q1

TEVIMBRA – 302 2L ESCC JP

TEVIMBRA – 306 1L ESCC US\*, JP

#### Q2

BRUKINSA – additional ~12 global approvals

TEVIMBRA – 305 1L GC AU

TEVIMBRA – 302 2L ESCC US Alt Dosing Q2/4W

TEVIMBRA – additional ~5 global approvals

### 2H, 2025

BRUKINSA – 114 Tablet formulation US, EU, AU

BRUKINSA – additional ~10 global approvals

TEVIMBRA – 305 1L GC BR, UK

TEVIMBRA – 306 1L ESCC BR, UK

TEVIMBRA – 309 1L NPC AU, CA, EU

TEVIMBRA – 312 1L ES-SCLC EU

TEVIMBRA – 315 Neo/adj NSCLC EU

TEVIMBRA – Alt Dosing Q2/4/6W US, AU (Q2/4W)

TEVIMBRA – additional ~45 global approvals

### 1H, 2026

BRUKINSA – 114 Tablet formulation UK

BRUKINSA – additional ~5 global approvals

TEVIMBRA – 302 2L ESCC CA

TEVIMBRA – 304 IL Non Sq NSCLC BR

TEVIMBRA – 305 1L GC CA

TEVIMBRA – 306 2L ESCC CA

TEVIMBRA – 307 IL Sq NSCLC BR

TEVIMBRA – 309 1L NPC UK

TEVIMBRA – 312 1L ES-SCLC UK

TEVIMBRA – 315 Neo/adj NSCLC UK

TEVIMBRA – Alt Dosing Q6W EU, CN

TEVIMBRA – additional ~18 global approvals

\* Due to a delay in scheduling clinical inspections, the target PDUFA date of July 2024 was deferred  
 BR - Brazil; CN - China; AU – Australia; JP - Japan; UK – United Kingdom; CA – Canada; EU – European Union  
 Refer to Glossary for other abbreviations

# BeiGene: Project Movements Since Q3 2024 Update

New to Phase 1/1b	New to Phase II	New to Pivotal Trial	New Submission <sup>1</sup>	Approved
<p><b>BG-60366-101</b> (EGFR-CDAC)</p> <p><b>BG-89894</b> (MAT2Ai)*</p> <p><b>BG-C477-101</b> (CEA ADC)</p> <p><b>BG-T187-101</b> (EGFRxMET)</p> <p><b>BGB-53038-101</b> (Pan-KRASi)</p> <p><b>BG-C137-101</b> (FGFR2b ADC)</p> <p><b>BGB-21447-102</b> (BCL2i 2G)</p> <p><b>BGB-B455-101</b> (Claudin6xCD3)</p>		<p><b>BGB-11417-302</b> (BCL2i)</p>	<p><b>Zanubrutinib 114</b> (tablet) in US, CH, AU</p> <p><b>Zanubrutinib 212</b> (R/R FL) in IL, MX, SA</p> <p><b>Zanubrutinib 304, 305</b> (R/R &amp; TN CLL, CLL PFS, WM) in TR; (CLL PFS update) in UY, SA, MX</p> <p><b>Zanubrutinib 214</b> (R/R MZL) in MY</p> <p><b>Tislelizumab 302</b> (2L ESCC) in PH, SA, TW</p> <p><b>Tislelizumab 305</b> (1L GC) in HK, IL, MO, PH, SA</p> <p><b>Tislelizumab 306</b> (1L ESCC) in HK, PH, SA, UK</p> <p><b>Tislelizumab 303, 304, 307</b> (1L/2L NSCLC) in HK, MO, PH, TW, SA</p> <p><b>Tislelizumab 309</b> (1L NPC) in EU, KR, SG</p> <p><b>Tislelizumab 312</b> (ES-SCLC) in EU, IS, NO</p> <p><b>Tislelizumab 315</b> (Neo/adj NSCLC) in EU, IS, NO</p> <p><b>Tislelizumab- Alt Dosing Q4W 2L</b> ESCC in US; <b>Q2/4W</b> in AU; <b>Q6W</b> in CN</p>	<p><b>Zanubrutinib 212</b> (R/R FL) in IL, SG</p> <p><b>Zanubrutinib 206</b> (R/R MCL) in UK</p> <p><b>Zanubrutinib 304, 305</b> (R/R &amp; TN CLL) in JP, RU; (PFS update) in EC, SG, RU</p> <p><b>Zanubrutinib 114</b> (tablet) in CA</p> <p><b>Tislelizumab 302</b> (2L ESCC) in HK, ID, MY, NZ</p> <p><b>Tislelizumab 305</b> (1L GC) in EU, IS, LI, NO, MO, US</p> <p><b>Tislelizumab 306</b> (1L ESCC) in AU, EU, IS, LI, NO</p> <p><b>Tislelizumab 303, 304, 307</b> (1L/2L NSCLC) in ID, NZ, UK</p> <p><b>Tislelizumab 303, 307</b> (1L sq/2L NSCLC) in IL</p> <p><b>Tislelizumab 312</b> (1L ES-SCLC) in MO</p> <p><b>Tislelizumab 315</b> Neo adj/adj NSCLC in CN</p>


AR - Argentina; AU - Australia; BR - Brazil; CA - Canada; CH - Switzerland; CN - China; EC - Ecuador; HK - Hong Kong; ID - Indonesia; IL - Israel; IN - India; IS - Iceland; JP - Japan; KR - South Korea; LI - Liechtenstein; MO - Macao; MX - Mexico; MY - Malaysia; NO - Norway; PH - Philippines; RS - Serbia; RU - Russia; SA - Saudi Arabia; SG - Singapore; TH - Thailand; TR - Turkey; UK - United Kingdom; US - United States; UY - Uruguay; NZ - New Zealand; TW - Taiwan

\* In licensed from CSPC



# Global Clinical Development Pipeline

Updated: 26 February 2025



Registration includes select accepted submissions in major markets.


† Trial is listed on clinicaltrials.gov but may not have subjects enrolled.

1) DualityBio collaboration, 2) CSPC collaboration, 3) Ensem collaboration, 4) Amgen collaboration, 5) Leads Biolabs collaboration, 6) Zymeworks/Jazz collaboration.

Please refer to our most recent 10-K filing for a full list of our commercial products, including in-licensed products, as well as commercial rights and collaboration details

- Heme
- Lung
- Breast / Gyn
- GI
- Pan-Tumor / Other
- Non-Oncology

# 12 Innovative Solid Tumor NMEs Entered the Clinic In 2024 In Priority Tumor Types with Diverse Modalities and Mechanisms



BeiGene has global rights for CDK2 (Ensem partnership), B7H4 ADC (DualityBio partnership), MAT2A (CSPC Zhongqi Pharmaceutical Technology); \* Not yet in the clinic

# BeiGene: Building Leadership in Solid Tumors with Innovative NMEs

	Phase 1			Phase 2		Phase 3		
<b>Breast/ Gynecologic Cancers</b>	BGB-C9074-101 B7H4-ADC Breast (other ST)	BGB-43395-101/102 CDK4i Breast (other ST)	BGB-21447* BCL2i 2G HR+ BC					
	BG-68501-101 CDK2i Breast (other ST)	BGB-24714-101 SMAC Solid Tumors	BGB-B455 Claudin6xCD3 Gyn (other ST) †					
<b>Gastro- intestinal</b>		BGB-B2033-101 GPC3x4-1BB Solid Tumors	BG-C137-101 FGFR2b ADC GI	BGB-LBL-007-201 LAG-3 MSS-CRC	BGB-LBL-007-202 LAG-3 1L ESCC		ZWI-ZW25-301 Zanidatamab HER2 1L HER2+ GEA	
	BG-53038-101 Pan-KRASI GI and lung	BG-C477-101 CEA ADC GI and Lung	BGB-B3227-101 MUC1xCD16A Lung and GI					
<b>Lung</b>	AMG757 20230298 Tarlatabam DLL3xCD3 2L+ SCLC (CN)	BGB-C354-101 B7H3 ADC Lung, GI and HNSCC	BG-T187 EGFRxMET Tsp Lung and GI	BGB-LC-201 Umbrella 1L NSCLC	BGB-LC-202 Umbrella Neoadjuvant NSCLC	AMG757 20230273 Tarlatabam DLL3xCD3 3L SCLC (CN)	AdvanTIG-302 Ociperlimab TIGIT 1L NSCLC (PDL1 high)	AMG757 20200041 Tarlatabam DLL3xCD3 1L ES-SCLC (CN)
	BG-60366-101 EGFR-CDAC Lung	BGB-58067-101 MTA-coop PRMT5i Lung and GI	BG-89894 MAT2Ai Lung and GI				AMG757 20210004 Tarlatabam DLL3xCD3 2L SCLC (CN)	AMG757 20230016 Tarlatabam DLL3xCD3 LS-SCLC (CN)
<b>Pan-tumor /Other</b>	BGB-30813-101 DGKζ Solid Tumors	BGB-A3055-101 CCR8 Solid Tumors	BGB-R046-101 Pro-IL15 Solid Tumors	BGB-HNSCC-201 Umbrella 1L HNSCC	BGB-A317-A445-201 BGB-A445 OX40 Melanoma and UC			
	BGB-15025-101 HPK1 Solid Tumors	BGB-26808-101 HPK1 2G Solid Tumors	AMG509 20180146 XaluritamigSTEAP1xCD3 mCRPC (CN)					

Refer to Glossary abbreviations

\* Additionally, in Ph1 in Heme indications.

† Trial is listed on clinicaltrials.gov, but may not have subjects enrolled



# BeiGene: Building Leadership in Solid Tumors With LCM

	Phase 1	Phase 2	Phase 3	Approved		
<b>Breast/ Gynecologic Cancers</b>			BGB-290-302 Pamiparib PARPi 2L+ MTx OC	BGB-290-102 Pamiparib PARPi 2L+ gBRCAm OC	Baituowei (Goserelin) Breast, Prostate	
<b>Gastro- intestinal</b>		BGB-A317-209 Tislelizumab PD-1 Resect MSI-H/ dMMR CRC		BGB-A317-301 Tislelizumab PD-1 1L HCC	BGB-A317-302 Tislelizumab PD-1 2L ESCC	BGB-A317-305 Tislelizumab PD-1 1L GC
				BGB-A317-306 Tislelizumab PD-1 1L ESCC	BGB-A317-208 Tislelizumab PD-1 2L/3L+HCC	
<b>Lung</b>				BGB-A317-304 Tislelizumab PD-1 1L Non-sq. NSCLC	BGB-A317-307 Tislelizumab PD-1 1L Sq. NSCLC	BGB-A317-303 Tislelizumab PD-1 2/3L NSCLC
				BGB-A317-312 Tislelizumab PD-1 1L ES-SCLC	BGB-A317-309 Tislelizumab PD-1 1L NPC	BGB-A317-315 Tislelizumab PD-1 Neo-adj./adj. NSCLC
<b>Pan tumor /Other</b>	BGB-A317-103 Tislelizumab PD-1 Subcutaneous		BGB-A317-310 Tislelizumab PD-1 1L UBC	BGB-A317-204 Tislelizumab PD-1 2L UC	BGB-A317-209 Tislelizumab PD-1 Late Line MSI-H or dMMR	
			BGB-A317-290-LTE1 Multiple BeiGene assets LTE Solid Tumors			

# BeiGene: a Leader in Hematology / I&I portfolio – Innovative NMEs

	Phase 1			Phase 2		Phase 3	
<b>AML/MDS, Multiple Myeloma, Other Heme</b>	<b>BGB-11417-103</b> Sonrotoclax BCL2i AML/MDS	<b>BGB-11417-105</b> Sonrotoclax BCL2i Multiple Myeloma t(11;14)					
<b>B-Cell</b>	<b>BGB-21447-101</b> BCL2i 2G B-Cell Malignancies			<b>BGB-11417-201</b> Sonrotoclax BCL2i R/R MCL	<b>BGB-11417-202</b> Sonrotoclax BCL2i CLL/SLL (China)	<b>BGB-11417-301</b> Sonrotoclax BCL2i TN CLL combo + zanu	
	<b>BGB-11417-102</b> Sonrotoclax BCL2i B-Cell Malig.(China)	<b>BGB-11417-101</b> Sonrotoclax BCL2i mono & combo w/ zanu		<b>BGB-11417-203</b> Sonrotoclax BCL2i R/R WM	<b>BGB-11417-204</b> Sonrotoclax BCL2i TN CLL	<b>BGB-11417-302</b> Sonrotoclax BCL2i R/R MCL	
	<b>BGB-16673-101</b> BTK CDAC B-Cell Malig.	<b>BGB-16673-102</b> BTK CDAC B-Cell Malig. (China)	<b>BGB-16673-104</b> BTK CDAC B-Cell Malig. combos	<b>BGB-16673-101/102</b> BTK CDAC R/R MCL & R/R CLL			
<b>I&amp;I</b>	<b>BGB-45035-101</b> IRAK4 CDAC Healthy volunteers						

# BeiGene: a Leader in Hematology / I&I With LCM

	Phase 1	Phase 2	Phase 3	Approved			
<b>AML/MDS, Multiple Myeloma, Other Heme</b>		<b>BLINCYTO®</b> CD3/CD19 BiTE Pediatric R/R BP-ALL	<b>BGB-A317-314</b> Tislelizumab PD-1 R/R cHL (China)	<b>BGB-A317-203</b> Tislelizumab PD-1 R/R cHL			
<b>B-Cell</b>		<b>BGB-3111-215</b> Zanubrutinib BTKi Prev. BTKi Tx intolerant	<b>BGB-3111-111</b> Zanubrutinib BTKi R/R CLL/SLL, WM, MCL (JP)	<b>BGB-3111-306</b> Zanubrutinib BTKi TN MCL	<b>BGB-3111-308</b> Zanubrutinib BTKi R/R MZL, R/R FL	<b>BGB-3111-206</b> Zanubrutinib BTKi R/R MCL	
		<b>BGB-3111-218</b> Zanubrutinib BTKi CD79B R/R DLBCL	<b>BGB-3111-304</b> Zanubrutinib BTKi TN CLL Ven combo	<b>BGB-3111-LTE1</b> Zanubrutinib BTKi B-cell malignancies		<b>BGB-3111-212</b> Zanubrutinib BTKi R/R FL	<b>BGB-3111-214</b> Zanubrutinib BTKi R/R MZL
						<b>BGB-3111-302</b> Zanubrutinib BTKi TN WM	
						<b>BGB-3111-304</b> Zanubrutinib BTKi TN CLL/SLL	<b>BGB-3111-305</b> Zanubrutinib BTKi R/R CLL/SLL
<b>I&amp;I</b>			<b>BGB-3111-309</b> Zanubrutinib BTKi PMN				



# Trial detail

- **BRUKINSA<sup>®</sup>** (zanubrutinib)
- **Sonrotoclax**
- **BGB-16673 BTK CDAC**
- **TEVIMBRA<sup>®</sup>** (tislelizumab)
- **Other Hematology Assets**
- **Other Solid Tumor Assets**
- **Immunology and Inflammation Assets**

# BRUKINSA®

## Foundational asset in hematology portfolio

Trial	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-3111-111	Phase 2	NCT04172246	B-Cell Malignancies	55		TEAEs and ORR	Maintenance (JP)
BGB-3111-215	Phase 2	NCT04116437	Previous BTKi Tx - ibru/acala intolerant	90		TEAEs	Maintenance
BGB-3111-218	Phase 2	NCT05068440	CD79b R/R DLBCL	66		ORR	Maintenance
BGB-3111-304	Phase 3	NCT03336333	TN CLL/SLL	590	Venetoclax	PFS	Maintenance
BGB-3111-306	Phase 3	NCT04002297	TN MCL	510	Rituximab	PFS	Maintenance
BGB-3111-308	Phase 3	NCT05100862	R/R MZL and FL	750	Rituximab, Obinutuzumab	PFS	Enrolling
BGB-3111-LTE1	Phase 3	NCT04170283	B-Cell Malignancies	500	Tislelizumab	TEAEs	Enrolling
BGB-3111-206	Phase 2	NCT03206970	R/R MCL	86		ORR	Approved
BGB-3111-212	Phase 2	NCT03332017	R/R NHL - FL	217	Obinutuzumab	ORR	Approved
BGB-3111-214	Phase 2	NCT03846427	R/R MZL	68		ORR	Approved
BGB-3111-302	Phase 3	NCT03053440	TN & R/R WM	201		CR/VGPR	Approved
BGB-3111-305	Phase 3	NCT03734016	R/R CLL	652		ORR	Approved



Refer to Glossary abbreviations



# Sonrotoclax

Potential best-in-class BCL2 inhibitor with differentiated profile

Trial	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-11417-101	Phase 1	NCT04277637	B-Cell Malignancies	437	Zanubrutinib, Obinutuzumab	TEAEs, MTD	Maintenance
BGB-11417-102	Phase 1	NCT04883957	B-Cell Malignancies	64		TEAEs, MTD	Maint. (CN)
BGB-11417-103	Phase 1	NCT04771130	AML/MDS	260	Azacitidine	TEAEs, CR, mOR	Enrolling
BGB-11417-105	Phase 1	NCT04973605	R/R MM with t(11;14)	167	Dexamethasone, Carfilzomib	TEAEs, ORR, VGPR, CR	Enrolling
BGB-11417-201	Phase 2	NCT05471843	Post-BTKi MCL	126		TEAEs, ORR	Maintenance
BGB-11417-202	Phase 2	NCT05479994	Post-BTKi CLL/SLL	100		ORR	Maintenance
BGB-11417-203	Phase 2	NCT05952037	R/R WM	105	Zanubrutinib	MRR	Enrolling
BGB-11417-204	Phase 2	NCT06637501	TN CLL	87	Zanubrutinib	CR/CRi	Enrolling
BGB-11417-301	Phase 3	NCT06073821	TN CLL/SLL	640	Zanubrutinib	PFS	Enrolling
BGB-11417-302	Phase 3	NCT06742996	R/R MCL	300	Zanubrutinib	PFS	Start Up

# BGB-16673 BTK CDAC

## Potential first-in-class BTK degrader

Trial	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-16673-101	Phase 1/2	NCT05006716	B-Cell Malignancies	466		TEAEs	Enrolling
BGB-16673-102	Phase 1	NCT05294731	B-Cell Malignancies	127		TEAEs, RP2D, ORR	Enrolling
BGB-16673-104	Phase 1/2	NCT06634589	B-Cell Malignancies	170	Sonrotoclax, Zanubrutinib	DLTs, TEAEs	Enrolling

# Phase 1 - Other Hematology Assets

Trial	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-21447-101	Phase 1	NCT05828589	B-cell malignancies	85		DLTs, AEs, TLS	Enrolling

# TEVIMBRA®

Poised for global patient impact

Trial	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-A317-310	Phase 3	NCT03967977	1L UBC	436	Chemotherapy	OS (ITT)	Enrolling
BGB-LC-201	Phase 2	NCT05635708	1L NSCLC	319	LAG3, OX40, HPK1, Chemotherapy	ORR	Maintenance
BGB-LC-202	Phase 2	NCT05577702	Neo/adj NSCLC	120	LAG3, Chemotherapy	MPR	Maintenance
BGB-A317-103	Phase 1	NCT06091943	Subcutaneous administration	69		Bioavailability and Safety	Maintenance
BGB-HNSCC-201	Phase 2	NCT05909904	1L HNSCC	160	LAG3, TIM3	ORR	Maintenance
BGB-A317-311	Phase 3	NCT03957590	Localized ESCC	366	Chemotherapy + Radiotherapy	PFS	Maintenance
BGB-A317-312	Phase 3	NCT04005716	1L ES-SCLC	455	Chemotherapy	OS	Approved*
BGB-A317-315	Phase 3	NCT04379635	Neo/adj NSCLC	450	Chemotherapy	MPR, EFS	Approved*
BGB-A317-203	Phase 2	NCT03209973	R/R cHL	68		ORR	Approved*
BGB-A317-204	Phase 2	NCT04004221	2L UC	110		ORR	Approved*



\* Approved only in China  
Refer to Glossary abbreviations

# TEVIMBRA®

Poised for global patient impact

Trial	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-A317-208	Phase 2	NCT03419897	2L+ HCC	250		ORR	Approved*
BGB-A317-209	Phase 2	NCT03736889	Late Line MSI-H or dMMR Solid Tumors	150		ORR	Approved*
BGB-A317-301	Phase 3	NCT03412773	1L HCC	680		OS	Approved*
BGB-A317-302	Phase 3	NCT03430843	2L ESCC	489		OS	Approved
BGB-A317-303	Phase 3	NCT03358875	2/3L NSCLC	805		OS (PDL1+), OS	Approved
BGB-A317-304	Phase 3	NCT03663205	1L Non-sq. NSCLC	334	Chemotherapy	PFS	Approved
BGB-A317-305	Phase 3	NCT03777657	1L GC	978	Chemotherapy	OS	Approved
BGB-A317-306	Phase 3	NCT03783442	1L ESCC	650	Chemotherapy	OS	Approved
BGB-A317-307	Phase 3	NCT03594747	1L Sq. NSCLC	342	Chemotherapy	PFS	Approved
BGB-A317-309	Phase 3	NCT03924986	1L NPC	263	Chemotherapy	PFS	Approved*



\* Approved only in China  
Refer to Glossary abbreviations



# Phase 1 - Other Solid Tumor Assets

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-290-102	Pamiparib	PARPi	Ph1	NCT03333915	Ovarian and breast cancer	128		TEAE, SAE, ORR	Approved
AMG509 20180146	Xaluritamig	STEAP1xCD3	Ph1	NCT04221542	mCRPC	9 (CN)		TEAE, DLTs	Enrolling
BGB-24714-101	BGB-24714	SMAC	Ph1	NCT05381909	Solid Tumors	229	Chemotherapy	AE, TEAE, SAE, DLT, MTD, RDFE, ORR	Expansion
BGB-A317-15025-101	BGB-15025	HPK1	Ph1	NCT04649385	Solid Tumors	169	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Maintenance
BGB-A317-30813-101	BGB-30813	DGKζ	Ph1	NCT05904496	Solid Tumors	81	Tislelizumab	TEAE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-A317-A3055-101	BGB-A3055	CCR8	Ph1	NCT05935098	Solid Tumors	89	Tislelizumab	TEAE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-C9074-101	BGB-C9074	B7H4 ADC	Ph1	NCT06233942	Solid Tumors	89	Tislelizumab	TEAE, SAE, DLT, MTD, RDFE, ORR, RP2D	Dose escalation
BG-68501-101	BG-68501	CDK2i	Ph1	NCT06257264	Solid Tumors	108	BGB-43395, Fulvestrant	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-C354-101	BGB-C354	B7H3 ADC	Ph1	NCT06422520	Solid Tumors	85	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-B2033-101	BGB-B2033	GPC3x4-1BB	Ph1	NCT06427941	Solid Tumors	140	Tislelizumab	AE, SAE, DLT, MTD, RP2D	Dose escalation
BGB-B3227-101	BGB-B3227	MUC1xCD16A	Ph1	NCT06540066	Solid Tumors	75	Tislelizumab, Chemotherapy	AE, SAE, DLT, MTD, RDFE	Dose escalation

# Phase 1 - Other Solid Tumor Assets

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-43395-101	BGB-43395	CDK4i	Ph1	NCT06120283	Solid Tumors	225	Fulvestrant, Letrozole	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-43395-102	BGB-43395	CDK4i	Ph1	NCT06253195	Solid Tumors	78	Fulvestrant, Letrozole	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-A317-26808-101	BGB-26808	HPK1 2G	Ph1	NCT05981703	Solid Tumors	90	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-R046-101	BGB-R046	IL-15 prodrug	Ph1	NCT06487858	Solid Tumors	74 (CN)	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BG-C477-101	BG-C477	CEA ADC	Ph1	NCT06596473	Solid Tumors	21	Chemotherapy	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BG-T187-101	BG-T187	EGFRxMET Tsp	Ph1	NCT06598800	Solid Tumors	87		AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BG-60366-101	BG-60366	EGFR CDAC	Ph1	NCT06685718	Solid Tumors	93		AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
SHY2039-001	BG-89894	MAT2Ai	Ph1	NCT06568614	Solid Tumors	60		AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation (CN)
BG-C137-101	BG-C137	FGFR2B ADC	Ph1	NCT06625593	Solid Tumors	68		AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BGB-53038-101	BGB-53038	Pan-KRASi	Ph1	NCT06585488	Solid Tumors	177	Tislelizumab Cetuximab	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BGB-58067-101	BGB-58067	PRMT5i	Ph1	NCT06589596	Solid Tumors	92		AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BGB-21447-102	BGB-21447	BCL2i	Ph1	NCT06756932	2L+HR+HER2- BC	92	Fulvestrant ± BGB-43395	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BGB-B455-101	BGB-B455	Claudin6xCD3	Ph1	NCT06803680 <sup>†</sup>	Solid Tumors	80		AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Not yet recruiting
AMG757 20230298	Tarlatamab	DLL3xCD3 (Subq)	Ph1	NCT06598306	2L+SCLC	10 (CN)		DLTs, TEAEs	Not yet recruiting (CN)

Refer to Glossary abbreviations

<sup>†</sup> Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

## Phase 2 - Other Solid Tumor Assets

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
AMG757 20230273	Tarlatamab	DLL3xCD3	Ph2	NCT06502977	3L+ SCLC	30 (CN)		ORR	Enrolling
BGB-A317-A445-201	BGB-A445	OX40	Ph2	NCT05661955	Melanoma, UC	191	Tislelizumab	ORR	Enrolling
BGB-LBL-007-201	BGB-LBL-007	LAG3	Ph2	NCT05609370	MSS-CRC	226	Tislelizumab, Chemotherapy, Bevacizumab	PFS, AE, SAE	Close-out
BGB-LBL-007-202	BGB-LBL-007	LAG3	Ph2	NCT06010303	1L ESCC	120	Tislelizumab, Chemotherapy	ORR	Close-out

# Phase 3 - Other Solid Tumor Assets

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
AMG757 20200041	Tarlatamab	DLL3xCD3	Ph3	NCT06211036	ES-SCLC	95 (CN)	Durvalumab	OS	Enrolling
AMG757 20230016	Tarlatamab	DLL3xCD3	Ph3	NCT06117774	LS-SCLC	77 (CN)		PFS	Enrolling
BGB-A317-290-LTE1	BeiGene assets	Multiple	Ph3	NCT04164199	Multiple	372#	Multiple	Immune mediated adverse events	Enrolling
ZWI-ZW25-301	Zanidatamab	HER2	Ph3	NCT05152147	1L HER2+ GEA	459	Tislelizumab ± Chemotherapy	PFS, OS	Enrolling*
AdvanTIG-302	Ociperlimab	TIGIT	Ph3	NCT04746924	1L NSCLC (PDL1 H)	671	Tislelizumab	OS	Maintenance
AMG757 20210004	Tarlatamab	DLL3xCD3	Ph3	NCT05740566	2L SCLC	98 (CN)		OS	Maintenance
BGB-290-302	Pamiparib	PARPi	Ph3	NCT03519230	Platinum-sensitive Recurrent OC	216		PFS	Maintenance

- \* Enrolling completed in BeiGene Territories
- #Currently enrolled patients, more patients may be enrolled in future
- Refer to Glossary abbreviations

# Immunology and Inflammation Assets

Trial	MOA	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
<b>BGB-3111-309</b>	BTKi	Ph3	NCT05707377	Primary Membranous Nephropathy	283		Urine Protein Creatinine Ratio, Complete Remission	Enrolling
<b>BGB-45035-101</b>	IRAK4 CDAC	Ph1	NCT06342713	Healthy volunteers	195		Adverse Events Cardiac Telemetry Vital signs	Enrolling



# Full List of Commercial and Clinical Assets

Commercial			Pipeline					
Product	Commercial Rights	Partner	Asset	Latest Stage	Partner	Asset	Latest Stage	Partner
BRUKINSA® (zanubrutinib)	Global	-	Sonrotoclax (BCL2i)	Ph3	-	Xaluritamig (STEAP1xCD3 XmAb®)*	Ph1	Amgen
TEVIMBRA® (tislelizumab)	Global	-	Ociperlimab (TIGIT mAb)	Ph3	-	BGB-45035 (IRAK4 CDAC)	Ph1	-
PARTRUVIX® (pamiparib)	Global	-	Zanidatamab (HER2 BsAb)	Ph3	Zymeworks/Jazz	BGB-C354 (B7H3 ADC)	Ph1	-
IMDELLTRA® (tarlatamab) <sup>1</sup>	China	Amgen	Tarlatamab (DLL3xCD3 BiTE®)*	Ph3	Amgen	BGB-R046 (IL-15 prodrug)	Ph1	-
XGEVA® (denosumab)	China	Amgen	BGB-16673 (BTK CDAC)	Ph2	-	BGB-B2033 (GPC3x4-1BB BsAb)	Ph1	-
BLINCYTO® (blinatumomab)	China	Amgen	-007 (LAG-3)	Ph2	Leads Biolabs	BGB-3227 (MUC1xCD16A BsAb)	Ph1	-
KYPROLIS® (carfilzomib)	China	Amgen	BGB-A445 (OX40)	Ph2	-	BG-T187 (EGFRxMET TsAb)	Ph1	-
SYLVANT® (siltuximab)	China	EUSA Pharma	BGB-21447 (BCL2i 2G)	Ph1	-	BG-C137 (FGFR2b ADC)	Ph1	-
QARZIBA® (dinutuximab)	China	EUSA Pharma	BGB-15025 (HPK1i)	Ph1	-	BGB-53038 (PanKRASi)	Ph1	-
POBEVCY® (Avastin biosimilar)	China	Bio-Thera	BGB-26808 (HPK1i 2G)	Ph1	-	BG-58067 (MTA Coop PRMT5i)	Ph1	-
BAITUOWEI® (goserelin microspheres for injection)	China	Luye Pharma	BGB-30813 (DGKζi)	Ph1	-	BG-C477 (CEA ADC)	Ph1	-
TAFINLAR® (dabrafenib)	China	Novartis	BGB-A3055 (CCR8 mAb)	Ph1	-	BG-89894 (MAT2Ai)	Ph1	CSPC
MEKINIST® (trametinib)	China	Novartis	BGB-24714 (SMAC mimetic)	Ph1	-			
VOTRIENT® (pazopanib)	China	Novartis	BGB-43395 (CDK4i)	Ph1	-			
AFINITOR® (everolimus)	China	Novartis	BG-60366 (EGFR CDAC)	Ph1	-			
ZYKADIA® (ceritinib)	China	Novartis	BGB-B455 (CLDN6 x CD3 BsAb) <sup>†</sup>	Ph1	-			
			BGB-68501 (CDK2i)	Ph1	Ensem			
			BG-C9074 (B7H4 ADC)	Ph1	Duality Bio			

<sup>†</sup> Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

<sup>1</sup>Amgen collaboration. BeiGene has tiered mid-single digit royalties on net sales

\* Study is being conducted in China as part of the BeiGene-Amgen collaboration

BeiGene holds commercial rights in China for REVLIMID® (lenalidomide) and VIDAZA® (azacitidine) through its BMS partnership until February 28, 2025

# Glossary

## Disease abbreviations

<b>AML</b>	Acute myeloid leukemia	<b>mCRPC</b>	Metastatic castration resistant prostate cancer
<b>BiTE</b>	Bi-specific T-cell engager	<b>MDS</b>	Myelodysplastic syndromes
<b>BP-ALL</b>	B-precursor acute lymphocytic leukemia	<b>MM</b>	Multiple myeloma
<b>BTC</b>	Biliary tract cancer	<b>MSI-H</b>	Microsatellite stability high
<b>CHL</b>	Classic Hodgkin's lymphoma	<b>MSS CRC</b>	Microsatellite stable colorectal cancer
<b>CLL</b>	Chronic lymphocytic leukemia	<b>MZL</b>	Marginal zone lymphoma
<b>dMMR</b>	Deficient DNA mismatch repair	<b>Neo/adj</b>	Neoadjuvant/adjuvant
<b>DLBCL</b>	Diffuse large B-cell lymphoma	<b>NSCLC</b>	Non-small cell lung cancer
<b>ES-SCLC</b>	Extensive stage small cell lung cancer	<b>NPC</b>	Nasopharyngeal carcinoma
<b>ESCC</b>	Esophageal squamous cell carcinoma	<b>OC</b>	Ovarian cancer
<b>FL</b>	Follicular lymphoma	<b>PMN</b>	Primary membranous nephropathy
<b>GEA</b>	Gastroesophageal adenocarcinoma	<b>R/R</b>	Relapsed or refractory
<b>GC</b>	Gastric cancer	<b>SCLC</b>	Small cell lung cancer
<b>HCC</b>	Hepatocellular cancer	<b>SLL</b>	Small lymphocytic lymphoma
<b>HNSCC</b>	Head and neck squamous cell carcinoma	<b>UC / UBC</b>	Urinary / bladder cancer
<b>LS-SCLC</b>	Limited stage small cell lung cancer	<b>WM</b>	Waldenström's macroglobulinemia
<b>MCL</b>	Mantle cell lymphoma		

## Other abbreviations

<b>ADC</b>	Antibody drug conjugate	<b>MTx</b>	Maintenance
<b>AE</b>	Adverse event	<b>ORR</b>	Objective response rate
<b>BiTE®</b>	Bi-specific T-cell engager	<b>OS</b>	Overall survival
<b>CDAC</b>	Chimeric degradation activation compound	<b>PCR</b>	Pathologic complete response
<b>CR</b>	Complete response	<b>PFS</b>	Progression-free survival
<b>DCR</b>	Disease control rate	<b>RDFE</b>	Recommended dose for expansion
<b>DLT</b>	Dose-limiting toxicity	<b>RP2D</b>	Recommended phase 2 dose
<b>DOR</b>	Duration of response	<b>SAE</b>	Severe adverse event
<b>EFS</b>	Event free survival	<b>TEAE</b>	Treatment emergent adverse event
<b>LCM</b>	Lifecycle management	<b>TN</b>	Treatment naïve
<b>LTE</b>	Long-term extension	<b>Tsp</b>	Tri-specific antibody
<b>mAb</b>	Monoclonal antibody	<b>VGPR</b>	Very good partial response
<b>mOR</b>	Modified overall response	<b>XmAb®</b>	XmAb is a registered trademark of Xencor, Inc.
<b>MPR</b>	Major pathological response		
<b>MTD</b>	Maximum tolerated dose		



 **BeiGene** →  **Beigene**

The image features a dark blue background with a blurred financial chart. The chart includes a bar graph and a line graph with data points. Several numerical values are visible: 12600.92, 20825.09, 15722.14, and 20825.09. The BeiGene logo is a red square with a white stylized 'B' and 'G' inside. The Beigene logo is a red square with a white stylized 'B' and 'G' inside, followed by the word 'Beigene' in white text.